Login to Your Account



Clinic Roundup


Tuesday, July 31, 2012
• Tonix Pharmaceuticals Holding Corp., of New York, reported that data from a comparative pharmacokinetic (PK) and bioavailability trial supported the continued development of TNX-102 (cyclobenzaprine) 2.4 mg sublingual tablets for bedtime administration to improve core fibromyalgia symptoms.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription